Uniglobe Travel Partners
2024 sales: $244.7 million
Previous ranking: 50
Employees: 80 full-time, 30 part-time
2603 Camino Ramon, Suite 200
San Ramon, CA 94583
Phone: (925) 838-4445
Website
$244.7 million5080 full-time, 30 part-time2603 Camino Ramon, Suite 200San Ramon, CA 94583Phone: (925) 838-4445
Executives
BOARD CHAIR: Andrew Henry
BOARD TREASURER: Ray Watson
BOARD SECRETARY: Mitchell Hicks
PRESIDENT: Noah Downer
COMPANY FACTS
* Privately held.
* Mitchell Hicks, Ray Watson and Uniglobe Travel USA are the three shareholders.
* Specializing in small-to-midsize enterprise business travel and leisure clients; a host agency division.
* Works with 550 independent contractors.
* 60% of sales completed by hosted advisors.
* Sales: 60% leisure, 40% business.
* A member of Uniglobe Travel network and Virtuoso.
DEVELOPMENTS
* Restructured and consolidated three operating divisions, which included hiring a new president, realigning management responsibilities and reviewing and revising processes and policies.
LOOKING AHEAD
* Increasing touchpoints and depth of client reviews.
* Expanding corporate sales activity.
* Targeting strategic acquisitions.
* Early 2025 has presented a mixed outlook. Several client sectors are growing, while others are hesitant because of macroeconomic and geopolitical issues.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Which Cryptocurrency Is More Likely to Be a Millionaire Maker? XRP vs. Cardano
XRP and Cardano might both grow significantly in the coming years. XRP's primary appeal is its strong association with institutional capital. Cardano's dedicated and active developer base could prove to be a major asset. 10 stocks we like better than XRP › XRP (CRYPTO: XRP) and Cardano (CRYPTO: ADA) have both been pitched as potential fast tracks to building up a hoard of seven figures. While it's generally not appropriate for serious investors to make purchases in the hopes of making millions overnight, over a long enough timescale, with enough diligent investment and the right asset selected, it is indeed possible. Between these two coins, both are well known, liquid, and still nowhere near their prior all‑time highs. That combination tempts bargain hunters. But price alone never mints millionaires, even in crypto; it's necessary to have a real set of fundamentals that'll drive a large influx of new capital even after a large amount has already shown up and stuck around. Let's examine which of these two actually has a credible shot at compounding long enough to turn persistent dollar‑cost averaging (DCA) into life‑changing gains. Let's start with some cold back-of-the-napkin arithmetic. XRP changes hands at about $2.19 today. A $10,000 position would need roughly a 100x gain to reach $1 million, at which point the coin's market cap would be roughly $11 trillion. For Cardano, it'd require a future market cap of around $2.3 trillion. Those numbers are long shots for both, but which chain has the better odds? Utility is a good starting proxy. On June 15, the XRP Ledger (XRPL) processed 5.1 million transactions in a single day, breaching its former records. That speaks directly to its core use case, which is to make cross-border transactions cheaper and faster than they would be using legacy technologies. High volume is a clear sign that its target user base, which is to say, institutional investors, are at least to some degree utilizing the chain for what it was intended to do. In contrast, Cardano lately averages closer to 50,000 daily transactions. It isn't precisely clear who the chain's target users are meant to be, but regardless of who it is, they do not appear to be actually using the chain very much at all in the grand scheme of things. That means it is less likely to grow rapidly. XRP also has an edge when it comes to competing in growth markets, like real‑world‑asset (RWA) tokenization. XRPL already hosts roughly $160 million in tokenized bonds, treasuries, and other off‑chain assets. Per some estimates, the tokenized asset market could grow from $0.6 trillion this year to reach $18.9 trillion by 2033. If XRP keeps compounding its early share of that pie, a pathway to triple‑digit gains exists. But Cardano has no comparable wedge into the same megatrend right now -- and, quite concerningly, it isn't actually exposed to any other trending growth segments either. Tech development is a major part of each coin's potential to make investors into millionaires. Once again, XRP takes the win. Ripple, the business that issues XRP, has spent 2025 adding tools that its core customer base actually wants. Ripple's developer summit this month unveiled identity‑layer upgrades that bake know‑your‑customer (KYC) regulatory compliance into the protocol, which is an existential requirement for large asset managers. Cardano, unfortunately, remains heavy on research papers and light on production traffic. Hydra, its long‑promised layer‑2 (L2) scaling system, is still in bug‑fix mode after recent security checks. Meanwhile, daily active wallet addresses hover near 24,000 -- far from being a user base of inspiring size. The chain's entire fee haul is less than $8,000 per day. Those metrics would be respectable for a start-up network, but they are tepid for a 9‑year‑old project. Developer activity is the lone area where Cardano shines, as in early 2025, it ranked among the top three chains in terms of updates pushed. Those high commit counts show some momentum, yet code is only valuable when users need what is being built, which is the main problem with the chain. Until Cardano's decentralized finance (DeFi) features become must‑have features for a defined audience, its robust research culture may not translate into price appreciation, and so far, it hasn't. For investors, the takeaway is clear. XRP is already solving paying customers' problems and charging fees to do so. Cardano is still refining the pitch. XRP is the coin that is more likely to make investors richer, but it probably won't deliver the eye-popping returns overnight that are necessary to make millionaires. Still, if the goal is to choose the stronger long‑term compounding machine, XRP currently offers better odds. Its growing transaction flow, embedded regulatory compliance features, and head start in the swelling RWA market create tangible revenue streams that can support higher valuations. Separately, Cardano remains an interesting technology play, and its staunch community plus academic rigor may yet pay off. For now, though, owning the coin is a wager that the team will eventually find a killer use case that drives non‑speculative demand. That might happen, but until it does, it is an investment thesis in search of evidence, not a smart place to put your capital. Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends XRP. The Motley Fool has a disclosure policy. Which Cryptocurrency Is More Likely to Be a Millionaire Maker? XRP vs. Cardano was originally published by The Motley Fool
Yahoo
29 minutes ago
- Yahoo
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
One major potential use case for AI in healthcare is drug discovery for pharmaceutical companies. Insurance is another healthcare-related industry likely to benefit from AI, which could aid scenario modeling, predictive analytics, and natural language processing. UnitedHealth Group experienced some operational challenges this year, but AI could wipe away these shortcomings in the long run. 10 stocks we like better than UnitedHealth Group › When it comes to popular healthcare stocks, investors have focused a lot of attention lately on Eli Lilly and Novo Nordisk and the potential of their blockbuster weight management treatments, including Mounjaro, Zepbound, Ozempic, and Wegovy. While these drugs are likely to lead to billions in revenue, Lilly and Novo aren't relying solely on these drugs to grow their businesses. Both companies are also looking into the potential that artificial intelligence (AI) can bring to their operations -- and for good reason. Accounting and consulting firm PwC estimates that the total addressable market (TAM) for AI in healthcare could reach $868 billion by 2030. One of the obvious applications that AI has for healthcare is facilitating pharmaceutical companies in clinical trials and drug discovery. While such use cases are exciting, I see another pocket of the healthcare industry that could be positively disrupted by AI: insurance. Let's explore why UnitedHealth Group (NYSE: UNH) could be an under-the-radar growth opportunity because of the intersection between healthcare and AI. Back in April, UnitedHealth greatly disappointed investors after the company published revised financial guidance that indicated a lower-than-expected earnings outlook for the remainder of the year. Management blamed the lower profitability on two primary factors. First, utilization rates in the company's Medicare Advantage program exceeded internal forecasts, taking a toll on the company's cost structure. Second, reimbursements in the company's pharmacy benefits management (PBM) platform, Optum Health, were negatively impacted by reductions in Medicare funding as well as changes to some of the patient demographic profiles in this segment of the business. In short order, the stock price plunged and has shown no indications of recovery, so far. For 2025, share prices are down 40%, making UnitedHealth the poorest-performing stock in the Dow Jones Industrial Average this year. But before you go writing UnitedHealth off as a broken business, let's examine how AI has the potential to help the health insurance industry and how UnitedHealth specifically could implement this technology to improve the business over time. The underlying issue surrounding UnitedHealth's challenges right now has to do with forecasting. There isn't anything fundamentally broken with the business. Rather, unforeseen changes in the macroeconomic environment led to a different reality than what management had previously modeled -- ultimately leading to higher costs and compressed profit margins. By using machine learning, UnitedHealth could train AI models on claims data and subsequently integrate these feeds into electronic health records (EHR) to help predict more accurate utilization trends. More efficient data feeds could help UnitedHealth hone its pricing strategy and better plan for cost spikes. In addition, AI has the ability to build predictive models that can more accurately assess patient risk profiles. In theory, this has the potential to analyze more granular detail around various segments of patient data as it relates to engagement rates and risk profiles. This could help improve reimbursement forecasts for the Optum business. Lastly, natural language processing (NLP) can also be used to create scenario models by simulating how a business could be impacted based on changes in the regulatory landscape. An example of a company that specializes in this area of AI training is FiscalNote. This could help UnitedHealth plan more strategically as it pertains to budgeting decisions during periods of political uncertainty. While shares of UnitedHealth trade at a slight premium to other large health insurers based on forward earnings multiples, the bigger takeaway from the trends below is that the stock price is hovering near a five-year low. While UnitedHealth's operational challenges won't be fixed overnight, it is key to remember that management believes the company can course correct throughout the second half of this year and be better positioned by 2026. Whether UnitedHealth transitions into an AI-powered service remains to be seen. Investors with a long-run time horizon might want to consider holding on to their shares, though, as the ideas explored above showcase how AI has the potential to become a game-changing advancement for the health insurance industry over time. Looked at a different way, UnitedHealth could transform its business over the next several years by making cognizant investments in this technology. Nevertheless, the stock appears dirt cheap right now, and I think patient investors will be rewarded as the company turns things around over the next couple of quarters. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Fiscal Note is a transcription service used by The Motley Fool. Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk and UnitedHealth Group. The Motley Fool has a disclosure policy. This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
3 Artificial Intelligence (AI) Stocks That Still Look Like Long-Term Winners
Palantir Technologies is a booming business, but its stock price continues to defy gravity. Apple is a legendary name, but its AI efforts haven't impressed. Alphabet faces a double-edged situation in AI. 10 stocks we like better than Palantir Technologies › When you consider whether to invest in a company for the long term, you'll often find that stocks fall into two groups. The first includes stocks of companies that have done well. For those, it's about whether they can continue to perform at a high level. The other consists of flawed stocks, companies facing adversity or potential challenges that may deter investors. Palantir Technologies (NASDAQ: PLTR), Apple (NASDAQ: AAPL), and Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) are three well-known technology stocks representing a mix of both groups. Palantir has been one of the market's biggest winners in artificial intelligence (AI), while investors wonder whether Apple and Alphabet are losing their edge. Here is the skinny on each name and why all three can still be long-term winners. Palantir Technologies continues to chug higher, racking up a blistering 2,100% gain since 2023. The company has become a leader in developing AI software on its proprietary platforms for government and enterprise customers. And since launching AIP, its AI-focused platform, in mid-2023, Palantir's growth has continued to accelerate. The company still has fewer than 500 commercial customers in the United States, a tiny fraction of the country's 20,000 large corporations. Then, you factor in Palantir's close military ties (government contracts accounted for 55% of revenue in Q1 2025) at a time when America is involved in numerous geopolitical conflicts, and it's easy to envision years of high-speed growth. Despite its best efforts, Palantir's business hasn't kept pace with its share price. The stock has rocketed to a forward P/E ratio of 245, which is excessive, to say the least, for a business expected to compound earnings at an annualized rate of 31% over the long term. Given its growth momentum, both in the government and with commercial customers, Palantir's business appears poised to continue winning. That said, investors will probably want to wait for some significant dips to buy the stock at a more reasonable valuation. AI seemed like a layup for Apple, with a wide-moat ecosystem spanning more than 2.35 billion active iOS devices worldwide. All Apple has needed to do is integrate AI capabilities into its iOS platform, and it would instantly be one of the leading consumer-facing AI companies, if not the leader. Yet Apple has struggled to launch notable AI features smoothly, and its underwhelming rollout of Apple Intelligence, its first attempt at AI, compelled the company to reorganize its AI team. The good news is that Apple's iOS remains one of the stickiest consumer ecosystems, which buys time for Apple to figure things out. People buy Apple products and use them for several years. The devices, whether it's a phone, computer, tablet, or watch, sync and work together. People become accustomed to iOS and develop a commitment to the ecosystem. Users may drift away from Apple eventually if it doesn't figure out AI, but it's unlikely that Apple's user base would implode overnight. Ultimately, Apple is a behemoth, a financial juggernaut with one of the world's most influential brands. While Apple may not deliver the same type of returns as in years past at a $3 trillion market cap, the stock should have a relatively high floor, based on the company's massive stock buybacks, growing dividend, and sticky business model. It's worth the leap of faith that Apple will solve its AI frustrations. Google's parent company, Alphabet, is facing some pressure from several directions. AI models have become popular enough to begin siphoning traffic away from traditional search engines, like Google. At the same time, U.S. regulators have successfully pursued litigation against Alphabet for anti-competitive practices, which could result in fines or even forced divestitures that would potentially impact its core advertising business. The adversity has one of the world's most prominent technology stocks trading at a P/E ratio of just 19 today. Yet, AI is arguably more an opportunity than a threat. Alphabet has integrated AI summaries into its search results, successfully monetizing them. Despite all the worries about AI, Google's ad revenue still grew by 10% in Q1 2025. Plus, Google Cloud is growing in size and profitability due to AI boosting demand for cloud services. If that weren't enough, Alphabet's autonomous ride-hailing business, Waymo, is continuing to expand its footprint across the United States and could eventually become a significant piece of Alphabet's business. When you put it all together, it seems that this technology giant will continue to remain a prominent force across the AI and technology space. That's an easy bet to make when the stock trades near its lowest valuation of the past decade. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Apple, and Palantir Technologies. The Motley Fool has a disclosure policy. 3 Artificial Intelligence (AI) Stocks That Still Look Like Long-Term Winners was originally published by The Motley Fool Sign in to access your portfolio
